<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766713</url>
  </required_header>
  <id_info>
    <org_study_id>EZE</org_study_id>
    <nct_id>NCT01766713</nct_id>
  </id_info>
  <brief_title>Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis</brief_title>
  <official_title>Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if the drug ezetimibe is a potential treatment for&#xD;
      Nonalcoholic Steatohepatitis(NASH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from&#xD;
      simple steatosis to nonalcoholic steatohepatitis (NASH), the progressive form of liver&#xD;
      disease that can lead to cirrhosis and liver-related mortality in persons who drink little or&#xD;
      no alcohol. Nonalcoholic steatohepatitis (NASH) represents the more severe end of this&#xD;
      spectrum and is characterized by steatosis, ballooning degeneration and lobular inflammation&#xD;
      with or without fibrosis. The etiology of NASH is not completely understood, but it is often&#xD;
      associated with obesity, type 2 diabetes, hyperlipidemia and insulin resistance.&#xD;
      Lipotoxicity, insulin resistance and oxidative stress appear to be central to the&#xD;
      pathogenesis of NASH. Currently, there is no FDA approved treatment for NAFLD/NASH. Weight&#xD;
      loss and exercise are the recommended but often difficult maintain these lifestyle changes in&#xD;
      the long term and therefore therapeutic agents have been investigated. Ezetimibe is an LDL&#xD;
      lowering agent that works through inhibition of the fat absorption from the small intestine.&#xD;
      In this study, we propose to treat 50 patients with NASH with either Ezetimibe or placebo for&#xD;
      24 weeks. After an initial evaluation for insulin sensitivity, MRI liver fat distribution and&#xD;
      liver biopsy, patients will receive either 10 mg/day of Ezetimibe or placebo. Patients will&#xD;
      be monitored at regular intervals for symptoms of liver disease, side effects of Ezetimibe&#xD;
      and serum biochemical and metabolic indices. At the end of 24-weeks, patients will have a&#xD;
      repeat medical evaluation, liver MRI and liver biopsy. Pre and post treatment MRI-derived&#xD;
      liver fat content, liver histology and insulin sensitivity will be compared. The primary end&#xD;
      point of successful therapy will be improvement in hepatic steatosis measured by MRI.&#xD;
      Secondary end points will be improvement in insulin sensitivity, liver histology and liver&#xD;
      biochemistry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Liver Fat as Measured by MRI-PDFF</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/day of Ezetimibe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet per day (identical to ezetimibe)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>10mg daily oral dose of ezetimibe</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Zetia, Ezetrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age at entry at least 18 years.&#xD;
&#xD;
          2. Serum alanine (ALT) or aspartate (AST) aminotransferase activities that are above the&#xD;
             upper limits of normal. 19 or more in women and 30 or more in men.&#xD;
&#xD;
          3. Evidence of hepatic steatosis or liver fat (&gt;5%) by MRI.&#xD;
&#xD;
          4. Evidence of definite or suspected NASH&#xD;
&#xD;
               1. Evidence of (definite) steatohepatitis on liver biopsy done within the previous&#xD;
                  12 months with a NASH activity score of at least 4 (of a total possible score of&#xD;
                  8) including a score of at least 1 each for steatosis, hepatocellular injury and&#xD;
                  parenchymal inflammation. Histological criteria of steatohepatitis include: (1)&#xD;
                  macrovesicular steatosis, (2) acinar zone 3 hepatocellular injury (ballooning&#xD;
                  degeneration), (3) parenchymal and (4) portal inflammation. Additionally helpful,&#xD;
                  but not required, features include the presence of (5) Mallory's hyaline and (6)&#xD;
                  pericellular and/or sinusoidal fibrosis that predominantly involves zone 3. If a&#xD;
                  liver biopsy is available within the last 12 months, then a repeat biopsy may not&#xD;
                  be conducted unless there has been a considerable change in body weight that may&#xD;
                  change liver histologic parameters associated with NASH&#xD;
&#xD;
               2. Those who are suspected of having NASH and have not undergone a liver biopsy&#xD;
                  within the last 12 months may undergo a liver biopsy as a screening liver biopsy&#xD;
                  but would qualify for randomization into either ezetimibe or placebo arms only if&#xD;
                  they meet histologic criteria of NASH.&#xD;
&#xD;
          5. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of another form of liver disease.&#xD;
&#xD;
               1. Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
               2. Hepatitis C as defined by presence of hepatitis C virus (HCV) RNA in serum.&#xD;
&#xD;
               3. Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or&#xD;
                  greater and liver histology consistent with autoimmune hepatitis or previous&#xD;
                  response to immunosuppressive therapy.&#xD;
&#xD;
               4. Autoimmune cholestatic liver disorders as defined by elevation of alkaline&#xD;
                  phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver&#xD;
                  histology consistent with primary biliary cirrhosis or elevation of alkaline&#xD;
                  phosphatase and liver histology consistent with sclerosing cholangitis.&#xD;
&#xD;
               5. Wilson disease as defined by ceruloplasmin below the limits of normal and liver&#xD;
                  histology consistent with Wilson disease.&#xD;
&#xD;
               6. Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than&#xD;
                  normal and liver histology consistent with alpha-1-antitrypsin deficiency.&#xD;
&#xD;
               7. Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy&#xD;
                  and homozygosity for C282Y or compound heterozygosity for C282Y/H63D.&#xD;
&#xD;
               8. Drug-induced liver disease as defined on the basis of typical exposure and&#xD;
                  history.&#xD;
&#xD;
               9. Bile duct obstruction as shown by imaging studies.&#xD;
&#xD;
          2. History of excess alcohol ingestion, averaging more than 30 gm/day (3 drinks per day)&#xD;
             in the previous 10 years, or history of alcohol intake averaging greater than 10&#xD;
             gm/day (1 drink per day: 7 drinks per week) in the previous one year.&#xD;
&#xD;
          3. Contraindications to liver biopsy: platelet counts &lt; 75,000/mm3 or prothrombin time&#xD;
             &gt;16 seconds or history of bleeding disorders&#xD;
&#xD;
          4. Decompensated liver disease, Child-Pugh score greater than or equal to 7 points&#xD;
&#xD;
          5. History of gastrointestinal bypass surgery or ingestion of drugs known to produce&#xD;
             hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate,&#xD;
             tetracycline or amiodarone in the previous 6 months.&#xD;
&#xD;
          6. Recent initiation or change of anti-diabetic drugs, including insulin, sulfonylureas,&#xD;
             or thiazolidinediones in the previous 90 days.&#xD;
&#xD;
          7. Use of ezetimibe or other agents in the same class within the 90 days prior to&#xD;
             randomization and/or liver biopsy.&#xD;
&#xD;
          8. Significant systemic or major illnesses other than liver disease, including congestive&#xD;
             heart failure, coronary artery disease, cerebrovascular disease, pulmonary disease&#xD;
             with hypoxia, renal failure, organ transplantation, serious psychiatric disease,&#xD;
             malignancy that, in the opinion of the investigator would preclude treatment with&#xD;
             ezetimibe and adequate follow up.&#xD;
&#xD;
          9. Positive test for anti-HIV.&#xD;
&#xD;
         10. Active substance abuse, such as alcohol, inhaled or injection drugs within the&#xD;
             previous one year.&#xD;
&#xD;
         11. Pregnancy or inability to practice adequate contraception in women of childbearing&#xD;
             potential.&#xD;
&#xD;
         12. Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml&#xD;
             and/or liver mass on imaging study that is suggestive of liver cancer.&#xD;
&#xD;
         13. Any other condition, which, in the opinion of the investigators would impede&#xD;
             competence or compliance or possibility hinder completion of the study.&#xD;
&#xD;
         14. Serum creatinine &gt;1.5 mg/dl.&#xD;
&#xD;
         15. Contraindications to ezetimibe use :&#xD;
&#xD;
               1. History of allergic reaction to ezetimibe&#xD;
&#xD;
               2. patients with acute liver injury or unexplained persistent elevations in ALT &gt;&#xD;
                  500 U/L&#xD;
&#xD;
               3. Women who are pregnant or may become pregnant&#xD;
&#xD;
               4. Nursing mothers&#xD;
&#xD;
         16. Contraindications to MRI:&#xD;
&#xD;
               1. The subject has any contraindication to MR imaging, such as patients with&#xD;
                  pacemakers, metallic cardiac valves, magnetic material such as surgical clips,&#xD;
                  implanted electronic infusion pumps or other conditions that would preclude&#xD;
                  proximity to a strong magnetic field.&#xD;
&#xD;
               2. The subject has a history of extreme claustrophobia&#xD;
&#xD;
               3. The subject cannot fit inside the MR scanner cavity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohit Loomba, MD, M.H.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 9, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <results_first_submitted>December 10, 2014</results_first_submitted>
  <results_first_submitted_qc>December 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2014</results_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Rohit Loomba</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine, Division of Gastroenterology, Department of Medicine and</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe</title>
          <description>10 mg/day of Ezetimibe&#xD;
Ezetimibe</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo identical to ezetimibe</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe</title>
          <description>10 mg/day of Ezetimibe&#xD;
Ezetimibe</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo only</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="14.9"/>
                    <measurement group_id="B2" value="49.5" spread="13.7"/>
                    <measurement group_id="B3" value="49.5" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Liver Fat as Measured by MRI-PDFF</title>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>compared to baseline, end of treatment MRI-PDFF</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg/day of Ezetimibe&#xD;
Ezetimibe</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo identical to ezetimibe</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Liver Fat as Measured by MRI-PDFF</title>
          <population>compared to baseline, end of treatment MRI-PDFF</population>
          <units>percentage of total fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="8.7"/>
                    <measurement group_id="O2" value="18.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="6.9"/>
                    <measurement group_id="O2" value="16.4" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe</title>
          <description>10 mg/day of Ezetimibe&#xD;
Ezetimibe</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo identical to 10 mg/day of Ezetimibe</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gall bladder perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI issues</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle soreness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rohit Loomba</name_or_title>
      <organization>UCSD</organization>
      <phone>858-534-2624</phone>
      <email>roloomba@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

